Jenscare Scientific Co. Ltd. Class H (HK:9877) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Jenscare Scientific Co. Ltd. has released encouraging six-month follow-up results from their TRAVEL II clinical trial, showing 97% device success and marked improvements in patients with severe tricuspid regurgitation. This includes significant enhancements in cardiac function and quality of life, with a promising safety profile for the LuX-Valve Plus, a transvascular tricuspid valve replacement system.
For further insights into HK:9877 stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue